A total of 43 innovative new medicines are anticipated to be approved or listed in Japan this year, according to a survey by Jiho. At the center of attention are some highly innovative, but probably ultra-expensive, gene therapies, as well…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS BMS CEO Sees Faster Drug Development as Industry Imperative after COVID Vaccine Feat
May 25, 2022
-
BUSINESS US Business Made or Broke FY2021 Earnings of Big 3 Generic Makers; Nichi-Iko, Sawai Suffer Losses
May 24, 2022
-
REGULATORY 2 mg Pen of Supply-Crippled Ozempic, 3rd Avastin Biosimilar Get Japan Listing
May 24, 2022
-
REGULATORY Japan’s Emergency Approval System Comes into Force, Nod Based on Presumed Efficacy
May 23, 2022
-
REGULATORY MOF Budget Examiner Presses for “Full” Annual Re-Pricing, Stepwise Cut in 2% Buffer Zone If No Reasonable Basis Given
May 20, 2022
-
REGULATORY Chuikyo OKs Listing of 14 Drugs on May 25, Biggest Peak Sales Forecast for Vabysmo
May 19, 2022
-
REGULATORY 4 Drugs Face Zero Premium Rule for Low Cost Disclosures: May Price Listing
May 19, 2022
-
BUSINESS Argenx CEO Sees Big Potential for Vyvgart with 100-Plus Diseases Driven by IgGs; Analysts Peg Peak Sales at US$5-10 Billion
May 18, 2022
-
BUSINESS AstraZeneca Ranks Third in Japan Sales Ranking with 12.1% Growth, Good Start in Q1 Too
May 18, 2022
-
ORGANIZATION PhRMA Urges Japan to Exclude Patented Products from Off-Year Re-Pricing in 2023, Create Innovation Ecosystem
May 17, 2022
-
BUSINESS Nichi-Iko Seeks Debt Workout amid US Pipeline Delays and Quality Woes, but President to Stay
May 16, 2022
-
BUSINESS Sumitomo Pharma Likely to Miss 5-Year Biz Targets as COVID Hobbles US Launches
May 16, 2022
-
REGULATORY Japan Clears Bill to Create Emergency Approval System, Enforcement Slated by Month-End
May 13, 2022
-
BUSINESS Shionogi Books 110 Billion Yen Sales for Yet-to-Be-Approved COVID Pill, Vaccine: FY2022 Outlook
May 12, 2022
-
BUSINESS Opdivo Projected to Grow 38% to 155 Billion Yen, but Ono Chief Sees No Re-Pricing
May 12, 2022
-
BUSINESS Jardiance Will Come Back as No. 1 in Japan SGLT2 Space after CKD Launch: NBI Chair
May 11, 2022
-
COMMENTARY Foreign Pharma Growing Vocal against Japan’s Pricing Policy, Flags Return of Drug Lag
May 10, 2022
-
ACADEMIA Difficult-to-Quantify Factors Should Be Reflected in Drug Prices to Establish VBP: Health Economist
May 9, 2022
-
REGULATORY Maruho’s Rozex in Line for Rosacea Nod in Japan
May 9, 2022
-
BUSINESS Astellas Logs 1st Sales Growth in 3 Years in FY2021; Chairman Hatanaka to Bow Out
April 28, 2022
ページ
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…